Literature DB >> 2605347

Nuclear characteristics as indicators of prognosis in node negative breast cancer patients.

V le Doussal1, M Tubiana-Hulin, K Hacene, S Friedman, M Brunet.   

Abstract

Nine clinical, biologic and histologic variables were evaluated for their significance in predicting the metastasis free survival (MFS) and the overall survival (OS) of 650 histologic node negative breast cancer patients. The variables studied were: menopausal status, UICC clinical stage of disease, Scarff-Bloom and Richardson (SBR) grade and its 3 components, estrogen and progesterone receptors, and anatomic tumor size. Multivariate Cox analyses revealed that histologic grade and clinical stage were the only significant prognostic factors for both MFS and OS. In the SBR grading system, grades I and III clearly have defined those patients with low and high risk for relapse, respectively. However, it is well known that more than 50% of the patients fall into the intermediate risk category, grade II, which provides essentially no useful prognostic information for those patients. To improve the assignment of patients to specific risk groups, a modified grade (MSBR), with five categories ordered according to the degree of malignancy, has been built from the nuclear pleomorphism and the mitotic index of the SBR grade. In combination with clinical stage, MSBR was found to be a prognostic indicator with high discriminatory power and caused the SBR grade to lose its significance. The first three categories of this MSBR may be gathered to designate low risk patients, whereas the last two categories, once combined, contain all the SBR grade III plus 57% of the SBR grade II tumors, and reliably identify high risk node negative patients. We suggest that a systemic adjuvant therapy should be discussed in this high risk group.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605347     DOI: 10.1007/bf01810737

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  35 in total

1.  [Anatomical localization of the first metastatic axillary lymph node of breast cancer (apropos of 73 cases having only 1 axilary node invaded)].

Authors:  G VOGT-HOERNER; G CONTESSO
Journal:  J Chir (Paris)       Date:  1963 Jul-Aug

2.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.

Authors:  G Contesso; H Mouriesse; S Friedman; J Genin; D Sarrazin; J Rouesse
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

3.  Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer.

Authors:  W L McGuire
Journal:  J Clin Oncol       Date:  1988-07       Impact factor: 44.544

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Predictors of recurrence in stage I (T1N0M0) breast carcinoma.

Authors:  P P Rosen; P E Saigo; D W Braun; E Weathers; A DePalo
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

6.  The histological grading of neoplasms.

Authors:  D E Henson
Journal:  Arch Pathol Lab Med       Date:  1988-11       Impact factor: 5.534

7.  Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.

Authors:  J Harvey; N de Klerk; I Berryman; G Sterrett; M Byrne; J Papadimitriou
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

8.  Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading.

Authors:  F F Parl; B P Schmidt; W D Dupont; R K Wagner
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

9.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

Authors: 
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  9 in total

1.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

2.  Nuclear pleomorphism, a strong prognostic factor in axillary node-negative small invasive breast cancer.

Authors:  M Stierer; H Rosen; R Weber
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

3.  The prognostic effect of histological tumor grade in node-negative breast cancer patients.

Authors:  M Schumacher; C Schmoor; W Sauerbrei; A Schauer; L Ummenhofer; W Gatzemeier; H Rauschecker
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 5.  Current management of carcinoma of the breast.

Authors:  T J Eberlein
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

Review 6.  Clinical decision-making in early breast cancer.

Authors:  C M Balch; S E Singletary; K I Bland
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

7.  Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index.

Authors:  G R Merlo; T Venesio; A Bernardi; L Canale; P Gaglia; D Lauro; A P Cappa; R Callahan; D S Liscia
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

8.  Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.

Authors:  M A Levesque; E P Diamandis; H Yu; D J Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Authors:  C Bouchet; F Spyratos; K Hacène; L Durcos; V Bécette; J Oglobine
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.